Transparency Market Research Report Added "Fragment-Based Drug Discovery Market" to its database.

Albany, NY -- (SBWire) -- 10/12/2015 --Fragment-based drug discovery (FBDD) is the phenomena of finding lead compounds during drug discovery procedure. It works on the principle of discovering small chemical fragments of drugs, which are weakly binded to the biological target and then these fragments are expanded or linked together to produce lead with larger affinity. Fragment-based drug discovery is majorly used in the pharmaceutical industry as it provides intractable biological targets. FBDD is slowly replacing the high-throughput screening (HTS) with respect to chemical lead generation for drug targets. HTS screens molecules with molecular weight of 500 Da in comparison to which, FBDD screens the molecule with molecular weight of 200 Da hence providing the better results.

Browse Full Report: http://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

On the basis of the techniques utilized for procedure, fragment-based drug discovery market is categorized into seven segments namely:
X-ray crystallography
Nuclear magnetic resonance (NMR) spectroscopy
Surface plasmon resonance (SPR)
Capillary electrophoresis
Mass spectroscopy
Differential scanning fluorimetry (DSF)
Mass spectroscopy
Among these, X-ray crystallography followed by NMR is majorly used by major market players to screen the fragment-based libraries. As for instance, Proteros Biostructures GmbH and Sygnature Discovery are working together on commercial fragment screening services, whereby Proteros Biostructures GmbH provides structural validation of fragment binding modes through X-ray crystallography and Sygnature Discovery designs and synthesize novel fragments. Nuclear magnetic resonance spectroscopy is also used by many companies such as Evotech AG is using NMR spectroscopy for screening purposes of MK2 ligand because NMR proves out to be more efficient in observing resonances of protein directly. Majorly two types of NMR spectroscopy are utilized for fragment-based drug discovery namely ligand detected NMR and protein detected NMR. Other than these various computation techniques such as docking software, post-docking analysis software and pharmacophore mapping software are also utilized for fragment-based drug discovery.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4741

Fragment-based drug discovery market is growing at faster pace due to the extensive use of the technique for research and development in drug discovery. R&D through fragment-based drug discovery market has yielded a vast pipeline of FBDD derived assets which are undergoing clinical evaluation. Recently, Plexicon's product vemurafenib, drug used to treat late stage melanoma has been approved by the Food and Drug Association. Other than this, many drugs such as ABT869, AT9283 and DG-051 are currently under phase 2 and phase 3 clinical trials. Higher ligand efficiency, more hydrophilic hits and less containment of sterically blocking groups are other factors that are also helping the market to grow. Fragment-based drug delivery market is also facing few restraints due to the need for highly sensitive screening devices and high cost involved with the procedure.

Companies based in North America and Europe has shown major interest in fragment-based drug discovery market majorly due to high government support towards research and development activities and availability of suitable infrastructure. As for example Abbott Laboratories has recently developed the drugs using fragment-based drug discovery which is focused on treating leukemia and liver cancer. These drugs are currently under phase II clinical trials. Asia-Pacific market is also growing at rapid rate due to increasing research and development activities in some countries such as Japan, China, Korea and India.

Some of the major market players in fragment-based drug discovery market include Astex Pharmaceuticals, BioPredict, Inc., Locus Pharmaceuticals, Cell Therapeutics, Inc., Schering-Plough Corporation, GlaxoSmithKline plc, deCODE Genetics, Eli Lilly and Company, Novaratis AG and Vernalis.

Read More Report on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Mr. Nachiket
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/